The Rettsyndrome.org and Neuren released the details of their second clinical trial using Trofinetide. Their press release said that trofinetide had significant clinical benefits and they were working with Neuren towards a third clinical trial.
The highest dose achieved statistically significant benefits compared to the placebo.